Welcome to the e-CCO Library Archive!
Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis
U. Kopylov1, T. Al-Taweel1, M. Yaghoobi2, W. Afif3, A. Bitton1, P.L. Lakatos4, S. Ben-Horin5, E.G. Seidman1, 1McGill University Health Center, Gastroenterology, Montreal, Canada, 2Medical University of South Carolina, Gastroenterology, Charleston, SC, United States, 3McGill University, Division of Gastroenterology, Montreal Quebec, Canada, 4Summelweis University, Gastroenterology, Budapest, Hungary, 5Sheba Medical Center, Gastroenterology, Ramat Gan, Israel
Thrombospondin 1 modulates monocyte properties to suppress intestinal mucosal inflammation
L. Fang*1, Z. Liu2
1The Shanghai Tenth People’s Hospital of Tongji University, Department of Gastroenterology, Shanghai , China, 2The Shanghai Tenth People’s Hospital of Tongji University, Department of Gastroenterology, Shanghai, China
Tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes
J. Panes1, C. Su2, A.G. Bushmakin3, J.C. Cappelleri3, C. Mamolo3, P. Healey3, 1Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 2Pfizer Inc, Collegeville, Pennsylvania, United States, 3Pfizer Inc, Groton, Connecticut, United States
Persistent dysregulated colonic mucosal gene expression in ulcerative colitis patients with endoscopic healing after infliximab or vedolizumab therapy
I. Arijs*1, G. De Hertogh2, L. Van Lommel3, K. Machiels1, J. Van der Goten1, M. Ferrante1, F. Schuit3, G. Van Assche1, P. Rutgeerts1, S. Vermeire1
1KU Leuven, Clinical and Experimental Medicine, Leuven, Belgium, 2KU Leuven, Imaging & Pathology, Leuven, Belgium, 3KU Leuven, Cellular and Molecular Medicine, Leuven, Belgium
Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab
B. Feagan1, J.-F. Colombel2, D. Rubin3, R. Mody4, S. Sankoh5, K. Lasch6, 1Western University/Robarts Research Institute, Robarts Clinical Trials Inc, London, Ontario, Canada, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 3The University of Chicago Medicine, Gastroenterology, Chicago, United States, 4Takeda Pharmaceuticals International, Inc., Global HEOR, Deerfield, United States, 5Takeda Pharmaceuticals International Company, Global Statistics, Cambridge, United States, 6Takeda Pharmaceuticals International Company, GI/Medical Affairs, Cambridge, United States
Impact of western diet on short-chain fatty acids production and host susceptibility to intestinal inflammation in a context of Crohn's Disease
A. Agus1, J. Denizot1, J. Thévenot1, S. Massier1, S. Denis2, A. Bernalier-Donadille3, E. Billard1, N. Barnich*1
1Université d'Auvergne, M2iSH, UMR INSERM/Université d’Auvergne U1071; Unité Sous Contrat Institut National de la Recherche Agronomique 2018,, Clermont-Ferrand, France, 2Université d'Auvergne, EACIDAM, Clermont-Ferrand, France, 3INRA, UR454, Saint-Genès-Champanelle, France
Low-dose budesonide maintains clinical remission and quality of life in collagenous colitis over a one year period: Results from the randomised, placebo-controlled BUC-63/COC trial
A. Münch1, J. Bohr2, S. Miehlke3, C. Benoni4, M. Olesen5, Å. Öst6, L. Strandberg7, P.M. Hellström8, E. Hertervig9, P. Armerding10, J. Stehlik11, G. Lindberg12, J. Björk12, A. Lapidus13, R. Löfberg14, O. Bonderup15, S. Avnström16, M. Rössle17, R. Muelller18, R. Greinwald18, C. Tysk19, M. Ström1, 1University Hospital, Gastoenterology and Hepatology, Linköping, Sweden, 2University Hospital, Gastroenterology, Örebro, Sweden, 3Center for Digestive Disease, Gastroenterology, Hamburg, Germany, 4University Hospital, Gastoenterology and Hepatology, Malmö, Sweden, 5University Hospital, Pathology, Malmö, Sweden, 6Medilab, Pathology, Stockholm, Sweden, 7Regional Hospital, Gastroenterology, Falun, Sweden, 8University Hospital, Gastoenterology and Hepatology, Uppsala, Sweden, 9University Hospital, Gastoenterology and Hepatology, Lund, Sweden, 10Private Practice, Gastroenterology, Berlin, Sweden, 11Regional Hospital, Gastroenterology, Usti nad Labem, Czech Republic, 12University Hospital, Gastroenterology, Stockholm, Sweden, 13Ersta hospital, Gastroenterology, Stockholm, Sweden, 14Sophiahemmet, IBD-Unit, Stockholm, Sweden, 15Regional Hospital, Gastroenterology, Silkeborg, Sweden, 16Regional Hospital, Gastroenterology, Copenhagen, Denmark, 17Private Practice, Gastroenterology, Freiburg, Germany, 18Dr. Falk Pharma, Research, Freiburg, Germany, 19University Hospital, Gastoenterology and Hepatology, Örebro, Sweden
Involvement of type VI secretion systems in virulence of adherent-invasive Escherichia coli isolated from patients with Crohn's disease
S. Massier1, S. Miquel2, N. Dreux1, A. Agus1, S. Bouhours1, J. Denizot1, A. Darfeuille-Michaud1, N. Barnich*1
1Université d'Auvergne, M2iSH, UMR INSERM/Université d’Auvergne U1071; Unité Sous Contrat Institut National de la Recherche Agronomique 2018,, Clermont-Ferrand, France, 2Université d'Auvergne, LMGE, Clermont-Ferrand, France
Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members
S. Danese1, G. Fiorino1, P. Michetti2, 1Humanitas Research Hospital, IBD Center, Rozzano, Milan, Italy, 2Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland
Abnormal gut homing and activation profile of blood and colonic dendritic cells in paediatric Crohn's disease normalises in response to nutritional therapy.
R. Vora*1, D. Bernardo2, J. Fell3, J. Fell3, H. Al-Hassi2, S. Knight2, A. Hart4
1Imperial College, Antigen Presentation Research Group, London, United Kingdom, 2Imperial College London, Antigen Presentation Research Group(APRG), London, United Kingdom, 3Chelsea and Westminster Hospital, Paediatric Gastroenterology, London, United Kingdom, 4St Mark's Hospital, Department of IBD, Colorectal Surgery and Wolfson Unit of Endoscopy, London, United Kingdom
Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron
C. Gasche1, Z. Tulassay2, T. Ahmad3, A. Stallmach4, for the AEGIS Study Group, 1Medical University of Vienna, Vienna, Austria, 2Semmelweis University, Budapest, Hungary, 3Royal Devon and Exeter Hospital, Exeter, United Kingdom, 4Friedrich Schiller University Jena, Jena, Germany
Pro-inflammatory effect of volcanic ash (v.ash) in a colitis model - is the v. ash or some of its components linked with the IBD epidemiology?
M.L. Orsini Delgado1, A. Sambuelli2, R. Papa Gobbi1, A. Gil2, S. Negreira2, S. Goncalves2, S. Huernos2, M. Bellicoso2, P. Tirado2, P. Chavero2, G. Docena*1
1Instituto de Estudios Inmunológicos y Fisiopatológicos IIFP, Facultad de Cs. Exactas - UNLP , La Plata - Bs. As., Argentina, 2IBD Section - Hospital Bonorino Udaondo, Medicine, Buenos Aires, Argentina
Increasing colectomy rates over time in ulcerative colitis and the impact of thiopurines: A nationwide cohort study
V. Chhaya1, S. Saxena2, E. Cecil2, A. Majeed2, R. Pollok1, 1St George's University of London, Gastroenterology, London, United Kingdom, 2Imperial College London, Primary care and Public Health, London, United Kingdom
iNKT cells contribute to Ulcerative Colitis through a Th1/Th17 immune response
C. Burrello1, G. Pellegrino2, G. Nizzoli3, A. Di Sabatino4, F. Caprioli5, 6, M. Rescigno1, F. Facciotti*1
1European Institute of Oncology, Experimental Oncology, Milan, Italy, 2Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti,, Milan, Italy, 3Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Milan, Italy, 4University of Pavia, Department of Internal Medicine, Pavia, Italy, 5University of Milan, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Milan, Italy, 6Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milan, Italy
Long-term natural history of postoperative recurrence in patients on preventive treatment with azathioprine
M. Mañosa1, Y. Zabana2, L. Marin1, I. Bernal1, J. Boix1, M. Piñol1, E. Cabré1, E. Domènech1, 1Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 2Hospital Universitario Mutua de Terrassa and CIBERehd, Gastroenterology Unit, Terrasa, Spain
Soft ROCK inhibition prevents intestinal fibrosis in a murine colitis model
T. Holvoet*1, S. Devriese1, K. Castermans2, S. Boland2, P. Hindryckx1, A. Borin2, M. De Vos1, O. Defert2, D. Laukens1
1Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium, 2Amakem, Therapeutics, Diepenbeek, Belgium
Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care
G. D'Haens1, B.L. Bressler2, S. Danese3, P.R. Gibson4, S.B. Hanauer5, W.J. Sandborn6, 1Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 2University of British Columbia, Dept of Gastroenterology, Vancouver, Canada, 3Istituto Clinico Humanitas IRCCS in Gastroenterology, Gastroenterology, Milan, Italy, 4Monash University, Dept of Gastroenterology, Box Hill, Australia, 5University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States, 6University of California San Diego, Division of Gastroenterolgy, San Diego, United States
Genome-wide association identifies multiple collagenous colitis susceptibility loci
G. Roda1, J. Torres2, J. Hu3, K. Hao3, Z. Zhongyang3, A. Chen4, R. Petras5, D. Pardi6, A. Juga7, G. Levi3, W. Cao8, F. Rieder9, I. Gordon10, N. Harpaz*11, J. Cho12, I. Peter3, J.-F. Colombel12
1Icahn School of Medicine, Gastroenterology, New York, United States, 2Hospital Beatriz Ângelo, Gastroenterology, loures, Portugal, 3Icahn School of Medicine at Mount Sinai, Medicine, New York, United States, 4Icahn School of Medicine at Mount Sinai, Gastroenterology , New York, United States, 5Ameripath, Pathology, Cleveland, United States, 6Mayo Clinic, Gastroenterology, Rochester, United States, 7NewYork-Presbyterian, Pathology, New York, United States, 8University of Rochester, Pathology, Rochester, United States, 9University of Cleveland, Gastroenterology, Cleveland, United States, 10Cleveland Clinic, Department of Anatomic Pathology, Cleveland Ohio, United States, 11Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 12Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States
Prospective, longitudinal observational study in therapeutic management of mild to moderate ulcerative colitis (OPTIMUM): follow-up at one year
S. Nahon1, G. Tucat2, P. Niez3, G. Bonnaud4, 1Centre Hospitalier Le Raincy, Gastroenterology, Montfermeil, France, 2CREGG, Gastroenterology, Paris, France, 3Ferring Pharmaceuticals France, Medical, Gentilly, France, 4Clinique des Cèdres, Cornebarrieu, France
Comparison of Disease Phenotype in 35,128 European and 4,686 non-European IBD Cohort of the IIBDGC
C.W. Lees*1, S. Ng2, R. Weersma3, I. IBD Genetics Consortium4
1Western General Hospital, GI Unit, Edinburgh, United Kingdom, 2Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, Medicine and Therapeutics, Chinese University of Hong Kong, China, 3University Medical Centre Groningen, Department of Gastroenteorlogy and Hepatology, Groningen, Netherlands, 4IIBDGC, Genetics, Global, United Kingdom